News & Updates

Show Multimedia Only

Adalimumab vs cyclosporine: Which is better for dermatological symptoms in VKH disease?

29 Aug 2025

Immunosuppression with prednisone plus either adalimumab or cyclosporine is effective in improving alopecia, but neither treatment does not provide any significant impact on the presence of vitiligo or poliosis in patients with Vogt-Koyanagi-Harada (VKH) disease at 6 months, reports a study.

Adalimumab vs cyclosporine: Which is better for dermatological symptoms in VKH disease?

29 Aug 2025

Cell harvesting device delivers repigmentation in stable vitiligo lesions

27 Aug 2025 by

A cell harvesting device that prepares autologous skin cell suspension (ASCS) offers a simple yet accessible technique for melanocyte transplantation in patients with vitiligo, a study has shown.

Cell harvesting device delivers repigmentation in stable vitiligo lesions

27 Aug 2025

Prademagene zamikeracel promotes wound healing in rare genetic skin disease

26 Aug 2025

In patients with large chronic wounds secondary to recessive dystrophic epidermolysis bullosa (RDEB), treatment with prademagene zamikeracel helps with wound healing and pain while being well tolerated, according to a phase III study.

Prademagene zamikeracel promotes wound healing in rare genetic skin disease

26 Aug 2025

$Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement$

Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement

07 Aug 2025 by

A Chinese man in his late 30s with a history of pulmonary tuberculosis, asthma, and nephritis, all in remission, presented to the clinic in November 2024 with worsening atopic dermatitis (AD). He had previously used oral systemic steroids (up to 30 mg daily) and azathioprine (up to 100 mg daily), with only mild response, leading to the discontinuation of these treatments. Upon examination, the patient exhibited itchy, scaly red patches on his central face, ears, neck, upper trunk, and elbows, with significant erosions. The body surface area involvement was 50 percent. Find out how this patient responded to oral abrocitinib treatment.

Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement

07 Aug 2025

Hidradenitis suppurativa patients vulnerable to mental disorders

05 Aug 2025 by

Patients with hidradenitis suppurativa (HS) face increased risks of depression and anxiety, as reported in a study.

Hidradenitis suppurativa patients vulnerable to mental disorders

05 Aug 2025

Specific vitamins may curb atopic dermatitis risk in young Chinese adults

31 Jul 2025 by

Higher dietary intake of vitamins E, K1, C, B2, and D appears to mitigate the risk of atopic dermatitis in young Chinese adults from Singapore and Malaysia, as shown in a large study.

Specific vitamins may curb atopic dermatitis risk in young Chinese adults

31 Jul 2025

Is radiologic imaging necessary in cutaneous SCC?

30 Jul 2025 by

Radiologic imaging of high-risk cutaneous squamous cell carcinoma (sSCC) tumours displays unforeseen results such as local invasion and nodal metastasis, which result in changes in management in nearly half of these cases, reveals a study.

Is radiologic imaging necessary in cutaneous SCC?

30 Jul 2025

Abrocitinib, dupilumab restore skin barrier function in AD

30 Jul 2025

Treatment with abrocitinib or dupilumab results in the restoration of skin barrier function in patients with atopic dermatitis (AD), but these therapies show distinct proteomic impacts, according to a study.

Abrocitinib, dupilumab restore skin barrier function in AD

30 Jul 2025

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

30 Jul 2025 by

Secukinumab may facilitate partial erosion repair and prevent enthesiophyte progression in patients with psoriatic arthritis (PsA), according to a phase IV randomized clinical trial (RCT).

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

30 Jul 2025

Daily emollient application in infants a feasible way to reduce AD burden

28 Jul 2025

Daily emollient application in infants helps reduce the cumulative incidence of atopic dermatitis throughout the 2 years of life and may be a feasible way to reduce its burden in communities, according to a study.

Daily emollient application in infants a feasible way to reduce AD burden

28 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Adalimumab vs cyclosporine: Which is better for dermatological symptoms in VKH disease?

Adalimumab vs cyclosporine: Which is better for dermatological symptoms in VKH disease?

Cell harvesting device delivers repigmentation in stable vitiligo lesions

Cell harvesting device delivers repigmentation in stable vitiligo lesions

Prademagene zamikeracel promotes wound healing in rare genetic skin disease

Prademagene zamikeracel promotes wound healing in rare genetic skin disease

Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement

Rapid resolution of refractory atopic dermatitis with abrocitinib: A case study focused on head and neck involvement

Hidradenitis suppurativa patients vulnerable to mental disorders

Hidradenitis suppurativa patients vulnerable to mental disorders

Specific vitamins may curb atopic dermatitis risk in young Chinese adults

Specific vitamins may curb atopic dermatitis risk in young Chinese adults

Is radiologic imaging necessary in cutaneous SCC?

Is radiologic imaging necessary in cutaneous SCC?

Abrocitinib, dupilumab restore skin barrier function in AD

Abrocitinib, dupilumab restore skin barrier function in AD

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

Secukinumab may reverse and prevent joint damage in psoriatic arthritis

Daily emollient application in infants a feasible way to reduce AD burden

Daily emollient application in infants a feasible way to reduce AD burden